Drug combo for advanced HER2 bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) as a first treatment for people with advanced HER2-positive or HER2-low bile duct or gallbladder cancer. The goal is to see if this combination helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced bile duct or gallbladder cancer that cannot be removed by surgery.
- Your cancer tests positive for HER2 or has low HER2 levels.
- You have not had any chemotherapy, targeted therapy, or immunotherapy for advanced disease.
- You are at least 18 years old and able to care for yourself (ECOG score 0 or 1).
- Your organs (liver, kidneys, bone marrow) are working well enough based on blood tests.
- You are willing to use effective birth control during and for 7 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has HER2 protein on its cells. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs (disitamab vedotin, lenvatinib, and a PD-1 inhibitor) for people with advanced bile duct cancer that has a protein called HER2. The goal is to see if this treatment can shrink or control the cancer.
This trial tests a new combination of two drugs (trastuzumab rezetecan and adebrelimab) against standard treatments for women with triple-negative breast cancer that wasn't completely removed by chemotherapy. The goal is to see if this combination works better at preventing the cancer from coming back.
This trial tests a combination of four drugs for people with advanced bile duct or gallbladder cancer that has spread. The drugs target HER2, a protein on some cancer cells, and may help shrink tumors or slow their growth.
This study tests a new combination of drugs for advanced bile duct cancer that has not been treated yet and shows a protein called HER2. It compares the new combination to the standard treatment to see if it works better or has fewer side effects.
This trial tests if adding trastuzumab to standard chemotherapy can help people with advanced bile duct or gallbladder cancer that tests positive for HER2. The study aims to see if the combination works better than chemotherapy alone.
Hear when a new Biliary Tract Neoplasms Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.